Dr Atul Malhotra and Dr Rebecca Lim |
Neonatologist Dr Atul Malhotra, and researchers Dr Rebecca
Lim and Professor Euan Wallace, received the award.
The clinical trial was the culmination of more than 10 years
research from the research and clinical team at Hudson Institute, Monash
Children’s Hospital and the School of Clinical Sciences at Monash Health
(Monash University).
The annual Awards were held at Monash Medical Centre in June
to celebrate the outstanding achievements, excellence and innovation of staff
at Monash Health.
Dr Malhotra says, “I am really excited to be part of this
study, which is a perfect example of bench-to-bedside research, enabled by the
collaborations between researchers and clinicians.”
The team conducted the first Phase I trial to test the
safety of cells derived from the placental amniotic membrane, in six premature
infants with severe bronchopulmonary dysplasia (BPD).
BPD or chronic lung disease of prematurity affects 50 to 60
per cent of extremely premature babies and starts when premature or immature
lungs are exposed to life-saving ventilation.
The study established the safety of the therapy, paving the
way for a larger Phase II trial, to determine the optimum cell dosage and
frequency involving 24 extremely premature babies at risk of developing BPD.
This study has recently started recruitment at Monash Health.
No comments:
Post a Comment